Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
12.5.2022 09:00:00 EEST | Business Wire | Press release
Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)
The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.
Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.
The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.
Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”
Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.
About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005724/en/
Contact information
Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com
Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RealPage Acquires Cherre, Creating a Trusted AI-Powered Intelligence Platform Across the Full Real Estate Capital Stack14.7.2026 16:03:00 EEST | Press release
RealPage, Inc., a leading provider of AI-enabled software and data analytics to the real estate industry, today announced it has completed its acquisition of Cherre, a real estate data intelligence company trusted by institutional owners, investment managers, and operators worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714560587/en/ RealPage now with Cherre. "AI can transform real estate only if it understands real estate," said Dirk Wakeham, President and Chief Executive Officer of RealPage. "Cherre has built the kind of trusted, governed intelligence that institutional owners and asset managers depend on. Bringing that expertise into RealPage means every customer, whether they manage one property or a global portfolio, gets access to a stronger, more trustworthy foundation for their decisions.” "We've always believed real estate organizations can't make confident decisions on data alone. They need a trusted,
Statement on Terminating the Letter of Intent With AI Financial Corporation14.7.2026 16:00:00 EEST | Press release
Statement from Matthew Nicoletti, Chief Strategy Officer, Perpetuals.com (Nasdaq: PDC), on the proposed transaction with AI Financial Corporation. “Perpetuals has decided not to further pursue the acquisition of AI Financial Corporation’s subsidiary Alt5 Sigma Canada, Inc. and the earlier letter of intent has been terminated.” About Perpetuals.com Ltd Perpetuals.com Ltd (Nasdaq: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to reduce risk through empowering retail users with intuitive, secure, and efficient trading experiences that span the world’s capital markets. UpsideOnly, the company's flagship consumer product, is the first risk-free trading platform, pairing human market insight with proprietary BayesShield AI so users can share in trading profits without ever risking their own money. Perpetuals’s proprietary AI system, BayesShield AI, combines advanced A
VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation14.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced VIVERE Group, a leading Indonesian one-stop solution provider for interior contracting, furniture manufacturing and furnishing, has selected Rimini Support™ for SAP to help maintain business continuity, strengthen support for its critical SAP ECC environment and free internal IT resources to focus on digital transformation initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714644251/en/ VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation Strengthening SAP support while advancing transformation Founded in 1984 and listed on the Indonesia Stock Exchange since 2002, PT Gema Graham Sarana Tbk (IDX: GEMA) has grown into the core company of VIVERE Group, running SAP ECC 6 on IBM Db2 as a crit
Rochester Electronics and Qorvo ® Team to Offer Long-Term Availability of RF Components14.7.2026 16:00:00 EEST | Press release
Rochester Electronics, LLC, a premier continuous source of authorized semiconductors, and Qorvo®, a leading global provider of connectivity and power solutions, today announced the completion of a worldwide distribution agreement. This collaboration significantly expands access to Qorvo’s RF and power high-performance semiconductor solutions for customers worldwide, with a particular emphasis on longevity of supply and lifecycle support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714526219/en/ Rochester Electronics and Qorvo® Team to Offer Long-Term Availability of RF Components Through Rochester Electronics’ unique position as a licensed manufacturer and authorized continuing source of semiconductors, Qorvo is extending the availability of its products to meet lifecycle design needs. This agreement not only helps ensure continuity for long-term applications but also contributes to technological sustainability by mini
InterSystems Recognized as a Leader in the Gartner® Magic Quadrant™ for Enterprise Electronic Health Records14.7.2026 16:00:00 EEST | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Electronic Health Records (EHR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714349759/en/ A Gartner Magic Quadrant is a culmination of research in a specific market, giving you a wide-angle view of the relative positions of the market’s competitors. By applying a graphical treatment and a uniform set of evaluation criteria, a Magic Quadrant helps you quickly ascertain how well technology providers are executing their stated visions and how well they are performing against Gartner’s market view. “Healthcare organizations are under pressure to modernize while continuing to deliver safe, reliable care every day,” said Don Woodlock, President of InterSystems. “The strength of our approach has always been combining prov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom